<?xml version="1.0" encoding="UTF-8"?>
<html><body class="spl" id="spl">
<div class="DocumentTitle"><p class="DocumentTitle"><strong>METHYLDOPA- methyldopa tablet, film coated </strong><br>Accord Healthcare Inc.<br></p></div>
<h1>Methyldopa Tablets, USP
 <br><br>
Rx only
</h1>
<div class="Contents">
<div class="Section" data-sectionCode="48780-1">
<a name="section-1"></a><p></p>
</div>
<div class="Section" data-sectionCode="34089-3">
<a name="s1"></a><a name="section-1"></a><p></p>
<h1>DESCRIPTION</h1>
<p class="First">Methyldopa is an antihypertensive and is the L-isomer of alpha-methyldopa. It is levo-3-(3,4-dihydroxyphenyl)-2-methylalanine sesquihydrate. Methyldopa
is supplied as tablets for oral administration, containing 125 mg, 250 mg and 500 mg of methyldopa. The amount of methyldopa is calculated on the anhydrous basis. Its molecular formula is C
       
 
  <span class="Sub">10</span>H
       
 
  <span class="Sub">13</span>NO
       
 
  <span class="Sub">4</span>• 1 1/2 H
       
 
  <span class="Sub">2</span>, with a molecular weight of 238.24, and its structural formula is:
      

 </p>
<div class="Figure"><img alt="Methyldopa structural formula" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=00206aae-7db1-4ae9-8500-b03fd6788d74&amp;name=structure.jpg"></div>
<p></p>
<p>Methyldopa is a white to yellowish white, odorless fine powder and is sparingly soluble in water.</p>
<p>The tablets contain the following inactive ingredients: pregelatinized starch, sodium starch glycolate, povidone, microcrystalline cellulose, magnesium
stearate, hypromellose, FD&amp;C yellow #6 lake and titanium dioxide. In addition 125 mg and 250 mg tablets contain corn starch.</p>
</div>
<div class="Section" data-sectionCode="34090-1">
<a name="s2"></a><a name="section-2"></a><p></p>
<h1>CLINICAL PHARMACOLOGY</h1>
<p class="First">Methyldopa is an aromatic-aminoacid decarboxylase inhibitor in animals and in man. Although the mechanism of action has yet to be conclusively
demonstrated, the antihypertensive effect of methyldopa probably is due to its metabolism to alpha-methylnorepinephrine, which then lowers arterial pressure by stimulation of central inhibitory alpha-adrenergic receptors, false neurotransmission, and/or reduction of plasma renin activity. Methyldopa has been shown to cause a net reduction in the tissue concentration of serotonin, dopamine, norepinephrine, and epinephrine.</p>
<p>Only methyldopa, the L-isomer of alpha-methyldopa, has the ability to inhibit dopa decarboxylase and to deplete animal tissues of norepinephrine. In man, the antihypertensive activity appears to be due solely to the L-isomer. About twice the dose of the racemate (DL-alpha-methyldopa) is required for equal antihypertensive effect.</p>
<p>Methyldopa has no direct effect on cardiac function and usually does not reduce glomerular filtration rate, renal blood flow, or filtration fraction. <span class="product-label-link" type="condition" conceptid="4221102" conceptname="Cardiac output">Cardiac output</span> usually is maintained without cardiac acceleration. In some patients the heart rate is slowed.</p>
<p>Normal or elevated plasma renin activity may decrease in the course of methyldopa therapy.</p>
<p>Methyldopa reduces both supine and standing blood pressure. It usually produces highly effective lowering of the supine pressure with infrequent
symptomatic <span class="product-label-link" type="condition" conceptid="319041" conceptname="Orthostatic hypotension">postural hypotension</span>. Exercise <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span> and diurnal blood pressure variations rarely occur.</p>
<div class="Section" data-sectionCode="43682-4">
<a name="s2.1"></a><a name="section-2.1"></a><p></p>
<h2>Pharmacokinetics and Metabolism</h2>
<p class="First">The maximum decrease in blood pressure occurs four to six hours after oral dosage. Once an effective dosage level is attained, a smooth blood pressure response occurs in most patients in 12 to 24 hours. After withdrawal, blood pressure usually returns to pretreatment levels within 24 to 48 hours.</p>
<p>Methyldopa is extensively metabolized. The known urinary metabolites are: α-methyldopa mono-0- sulfate; 3-0-methyl-α-methyldopa; 3,4-dihydroxyphenylacetone; α-methyldopamine; 3-0-methyl-α-methyldopamine and their conjugates.</p>
<p>Approximately 70 percent of the drug which is absorbed is excreted in the urine as methyldopa and its mono-o-sulfate conjugate. The renal clearance is about 130 mL/min in normal subjects and is diminished in <span class="product-label-link" type="condition" conceptid="192359" conceptname="Renal failure syndrome">renal insufficiency</span>. The plasma half-life of methyldopa is 105 minutes. After oral doses, excretion is essentially complete in 36 hours.</p>
<p>Methyldopa crosses the placental barrier, appears in cord blood, and appears in breast milk.</p>
</div>
</div>
<div class="Section" data-sectionCode="34067-9">
<a name="s3"></a><a name="section-3"></a><p></p>
<h1>INDICATIONS AND USAGE</h1>
<p class="First"><span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">Hypertension</span>.</p>
</div>
<div class="Section" data-sectionCode="34070-3">
<a name="s4"></a><a name="section-4"></a><p></p>
<h1>CONTRAINDICATIONS</h1>
<p class="First">Methyldopa is contraindicated in patients:</p>
<p>- with active <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic disease</span>, such as acute <span class="product-label-link" type="condition" conceptid="194990" conceptname="Inflammatory disease of liver">hepatitis</span> and active cirrhosis.</p>
<p>- with <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">liver disorders</span> previously associated with methyldopa therapy (see 
       
 
  <span class="Bold"><a href="#s5">WARNINGS</a></span>).
      

 </p>
<p>- with <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity</span> to any component of this product.</p>
<p>- on therapy with monoamine oxidase (MAO) inhibitors.</p>
</div>
<div class="Section" data-sectionCode="34071-1">
<a name="s5"></a><a name="section-5"></a><p></p>
<h1>WARNINGS</h1>
<p class="First"><span class="Bold">It is important to recognize that a positive Coombs test, <span class="product-label-link" type="condition" conceptid="435503" conceptname="Hemolytic anemia">hemolytic anemia</span>, and <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">liver disorders</span> may occur with methyldopa therapy. The rare occurrences of <span class="product-label-link" type="condition" conceptid="435503" conceptname="Hemolytic anemia">hemolytic anemia</span> or <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">liver disorders</span> could lead to potentially fatal complications unless properly recognized and managed. Read this section carefully to understand these reactions.</span></p>
<p>With prolonged methyldopa therapy, 10 to 20 percent of patients develop a positive direct Coombs test which usually occurs between 6 and 12 months of methyldopa therapy. Lowest incidence is at daily dosage of 1 g or less. This on rare occasions may be associated with <span class="product-label-link" type="condition" conceptid="435503" conceptname="Hemolytic anemia">hemolytic anemia</span>, which could lead to potentially fatal complications. One cannot predict which patients with a positive direct Coombs test may develop <span class="product-label-link" type="condition" conceptid="435503" conceptname="Hemolytic anemia">hemolytic anemia</span>.</p>
<p>Prior existence or development of a positive direct Coombs test is not in itself a contraindication to use of methyldopa. If a positive Coombs test develops during methyldopa therapy, the physician should determine whether <span class="product-label-link" type="condition" conceptid="435503" conceptname="Hemolytic anemia">hemolytic anemia</span> exists and whether the positive Coombs test may be a problem. For example, in addition to a positive direct Coombs test there is less often a positive indirect Coombs test which may interfere with cross matching of blood.</p>
<p>Before treatment is started, it is desirable to do a blood count (hematocrit, hemoglobin, or red cell count) for a baseline or to establish whether there is <span class="product-label-link" type="condition" conceptid="439777" conceptname="Anemia">anemia</span>. Periodic blood counts should be done during therapy to detect <span class="product-label-link" type="condition" conceptid="435503" conceptname="Hemolytic anemia">hemolytic anemia</span>. It may be useful to do a direct Coombs test before therapy and at 6 and 12 months after the start of therapy.</p>
<p>If Coombs-positive <span class="product-label-link" type="condition" conceptid="435503" conceptname="Hemolytic anemia">hemolytic anemia</span> occurs, the cause may be methyldopa and the drug should be discontinued. Usually the <span class="product-label-link" type="condition" conceptid="439777" conceptname="Anemia">anemia</span> remits promptly. If not, corticosteroids may be given and other causes of <span class="product-label-link" type="condition" conceptid="439777" conceptname="Anemia">anemia</span> should be considered. If the <span class="product-label-link" type="condition" conceptid="435503" conceptname="Hemolytic anemia">hemolytic anemia</span> is related to methyldopa, the drug should not be reinstituted.</p>
<p>When methyldopa causes Coombs positivity alone or with <span class="product-label-link" type="condition" conceptid="435503" conceptname="Hemolytic anemia">hemolytic anemia</span>, the red cell is usually coated with gamma globulin of the IgG (gamma G) class only. The positive Coombs test may not revert to normal until weeks to months after methyldopa is stopped.</p>
<p>Should the need for transfusion arise in a patient receiving methyldopa, both a direct and an indirect Coombs test should be performed. In the absence of <span class="product-label-link" type="condition" conceptid="435503" conceptname="Hemolytic anemia">hemolytic anemia</span>, usually only the direct Coombs test will be positive. A positive direct Coombs test alone will not interfere with typing or cross matching. If the indirect Coombs test is also positive, problems may arise in the major cross match and the assistance of a hematologist or transfusion expert will be needed.</p>
<p>Occasionally, <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">fever</span> has occurred within the first three weeks of methyldopa therapy, associated in some cases with <span class="product-label-link" type="condition" conceptid="4302954" conceptname="Disorder characterized by eosinophilia">eosinophilia</span> or abnormalities in one or more liver function tests, such as serum alkaline phosphatase, serum transaminases (<span class="product-label-link" type="condition" conceptid="4094657" conceptname="Aspartate aminotransferase">SGOT</span>, SGPT), bilirubin, and <span class="product-label-link" type="condition" conceptid="4173906" conceptname="Clotting factor II assay">prothrombin</span> time. <span class="product-label-link" type="condition" conceptid="137977" conceptname="Jaundice">Jaundice</span>, with or without <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">fever</span>, may occur with onset usually within the first two to three months of therapy. In some patients the findings are consistent with those of <span class="product-label-link" type="condition" conceptid="4143915" conceptname="Cholestasis">cholestasis</span>. In others the findings are consistent with <span class="product-label-link" type="condition" conceptid="194990" conceptname="Inflammatory disease of liver">hepatitis</span> and <span class="product-label-link" type="condition" conceptid="4352876" conceptname="Liver damage">hepatocellular injury</span>.</p>
<p>Rarely, fatal <span class="product-label-link" type="condition" conceptid="4337543" conceptname="Hepatic necrosis">hepatic necrosis</span> has been reported after use of methyldopa. These hepatic changes may represent <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity reactions</span>. Periodic determinations of hepatic function should be done particularly during the first 6 to 12 weeks of therapy or whenever an unexplained <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">fever</span> occurs. If <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">fever</span>, abnormalities in liver function tests, or <span class="product-label-link" type="condition" conceptid="137977" conceptname="Jaundice">jaundice</span> appear, stop therapy with methyldopa. If caused by methyldopa, the temperature and abnormalities in liver function characteristically have reverted to normal when the drug was discontinued. Methyldopa should not be reinstituted in such patients.</p>
<p>Rarely, a reversible reduction of the white blood cell count with a primary effect on the granulocytes has been seen. The granulocyte count returned promptly to normal on discontinuance of the drug. Rare cases of <span class="product-label-link" type="condition" conceptid="4218497" conceptname="Granulocytopenic disorder">granulocytopenia</span> have been reported. In each instance, upon stopping the drug, the white cell count returned to normal. Reversible <span class="product-label-link" type="condition" conceptid="432870" conceptname="Thrombocytopenic disorder">thrombocytopenia</span> has occurred rarely.</p>
</div>
<div class="Section" data-sectionCode="42232-9">
<a name="s6"></a><a name="section-6"></a><p></p>
<h1>PRECAUTIONS</h1>
<div class="Section" data-sectionCode="34072-9">
<a name="s6.1"></a><a name="section-6.1"></a><p></p>
<h2>General</h2>
<p class="First">Methyldopa should be used with caution in patients with a history of previous liver disease or dysfunction  (see 
         
 
  <span class="Bold"><a href="#s5">WARNINGS</a></span>).
        

 </p>
<p>Some patients taking methyldopa experience clinical <span class="product-label-link" type="condition" conceptid="433595" conceptname="Edema">edema</span> or <span class="product-label-link" type="condition" conceptid="4134784" conceptname="Weight increased">weight gain</span> which may be controlled by use of a diuretic. Methyldopa should not be continued if <span class="product-label-link" type="condition" conceptid="433595" conceptname="Edema">edema</span> progresses or signs of <span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">heart failure</span> appear.</p>
<p><span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">Hypertension</span> has recurred occasionally after dialysis in patients given methyldopa because the drug is removed by this procedure.</p>
<p>Rarely, involuntary choreoathetotic movements have been observed during therapy with methyldopa in patients with severe bilateral cerebrovascular disease. Should these movements occur, stop therapy.</p>
</div>
<div class="Section" data-sectionCode="34075-2">
<a name="s6.2"></a><a name="section-6.2"></a><p></p>
<h2>Laboratory Tests</h2>
<p class="First">Blood count, Coombs test and liver function tests are recommended before initiating therapy and at periodic intervals  (see 
         
 
  <span class="Bold"><a href="#s5">WARNINGS</a></span>).
        

 </p>
</div>
<div class="Section" data-sectionCode="34073-7">
<a name="s6.3"></a><a name="section-6.3"></a><p></p>
<h2>Drug Interactions</h2>
<p class="First">When methyldopa is used with other antihypertensive drugs, potentiation of antihypertensive effect may occur. Patients should be followed carefully to detect side reactions or unusual manifestations of drug idiosyncrasy.</p>
<p>Patients may require reduced doses of anesthetics when on methyldopa. If <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span> does occur during anesthesia, it usually can be controlled by vasopressors. The adrenergic receptors remain sensitive during treatment with methyldopa.</p>
<p>When methyldopa and lithium are given concomitantly, the patient should be carefully monitored for symptoms of <span class="product-label-link" type="condition" conceptid="433667" conceptname="Poisoning by tetanus vaccine">lithium toxicity</span>. Read the circular for lithium preparations.</p>
<p>Several studies demonstrate a decrease in the bioavailability of methyldopa when it is ingested with ferrous sulfate or ferrous gluconate. This may adversely affect blood pressure control in patients treated with methyldopa. Coadministration of methyldopa with ferrous sulfate or ferrous gluconate is not recommended.</p>
<p>Monoamine oxidase (MAO) inhibitors: See 
         
 
  <span class="Bold"><a href="#s4">CONTRAINDICATIONS</a></span>.
        

 </p>
</div>
<div class="Section" data-sectionCode="34074-5">
<a name="s6.4"></a><a name="section-6.4"></a><p></p>
<h2>Drug/Laboratory Test Interactions</h2>
<p class="First">Methyldopa may interfere with measurement of: urinary uric acid by the phosphotungstate method, serum creatinine by the alkaline picrate method, and <span class="product-label-link" type="condition" conceptid="4094657" conceptname="Aspartate aminotransferase">SGOT</span> by colorimetric methods. Interference with spectrophotometric methods for <span class="product-label-link" type="condition" conceptid="4094657" conceptname="Aspartate aminotransferase">SGOT</span> analysis has not been reported.</p>
<p>Since methyldopa causes fluorescence in urine samples at the same wave lengths as catecholamines, falsely high levels of urinary catecholamines may be reported. This will interfere with the diagnosis of <span class="product-label-link" type="condition" conceptid="4118993" conceptname="Pheochromocytoma">pheochromocytoma</span>. It is important to recognize this phenomenon before a patient with a possible <span class="product-label-link" type="condition" conceptid="4118993" conceptname="Pheochromocytoma">pheochromocytoma</span> is subjected to surgery. Methyldopa does not interfere with measurement of VMA (vanillylmandelic acid), a test for <span class="product-label-link" type="condition" conceptid="4118993" conceptname="Pheochromocytoma">pheochromocytoma</span>, by those methods which convert VMA to vanillin. Methyldopa is not recommended for the treatment of patients with <span class="product-label-link" type="condition" conceptid="4118993" conceptname="Pheochromocytoma">pheochromocytoma</span>. Rarely, when urine is exposed to air after voiding, it may darken because of breakdown of methyldopa or its metabolites.</p>
</div>
<div class="Section" data-sectionCode="34083-6">
<a name="s6.5"></a><a name="section-6.5"></a><p></p>
<h2>Carcinogenesis, Mutagenesis, Impairment of Fertility</h2>
<p class="First">No evidence of a tumorigenic effect was seen when methyldopa was given for two years to mice at doses up to 1800 mg/kg/day or to rats at doses up to 240 mg/kg/day. (30 and 4 times the maximum recommended human dose in mice and rats, respectively, when compared on the basis of body weight; 2.5 and 0.6 times the maximum recommended human dose in mice and rats, respectively, when compared on the basis of body surface area; calculations assume a patient weight of 50 kg).</p>
<p>Methyldopa was not mutagenic in the Ames Test and did not increase chromosomal aberration or sister chromatid exchanges in Chinese hamster ovary cells. These 
         
 
  <span class="Italics">in vitro </span>studies were carried out both with and without exogenous metabolic activation.
        

 </p>
<p>Fertility was unaffected when methyldopa was given to male and female rats at 100 mg/kg/day (1.7 times the maximum daily human dose when compared on the basis of body weight; 0.2 times the maximum daily human dose when compared on the basis of body surface area). Methyldopa decreased sperm count, sperm motility, the number of late spermatids and the male fertility index when given to male rats at 200 and 400 mg/kg/day. (3.3 and 6.7 times the maximum daily human dose when compared on the basis of body weight; 0.5 and 1 times the maximum daily human dose when compared on the basis of body surface area).</p>
</div>
<div class="Section" data-sectionCode="42228-7">
<a name="s7"></a><a name="section-6.6"></a><p></p>
<h2>Pregnancy</h2>
<div class="Section" data-sectionCode="34077-8">
<a name="s7.1"></a><a name="section-6.6.1"></a><p></p>
<h3>Teratogenic Effects. Pregnancy Category B</h3>
<p class="First">Reproduction studies performed with methyldopa at oral doses up to 1000 mg/kg in mice, 200 mg/kg in rabbits and 100 mg/kg in rats revealed no evidence of harm to the fetus. These doses are 16.6 times, 3.3 times and 1.7 times, respectively, the maximum daily human dose when compared on the basis of body weight; 1.4 times, 1.1 times and 0.2 times, respectively, when compared on the basis of body surface area; calculations assume a patient weight of 50 kg. There are, however, no adequate and well-controlled studies in pregnant women in the first trimester of pregnancy. Because animal reproduction studies are not always predictive of human response, methyldopa should be used during pregnancy only if clearly needed.</p>
<p>Published reports of the use of methyldopa during all trimesters indicate that if this drug is used during pregnancy the possibility of fetal harm appears remote. In five studies, three of which were controlled, involving 332 pregnant hypertensive women, treatment with methyldopa was associated with an improved fetal outcome. The majority of these women were in the third trimester when methyldopa therapy was begun.</p>
<p>In one study, women who had begun methyldopa treatment between weeks 16 and 20 of pregnancy gave birth to infants whose average head circumference was reduced by a small amount (34.2 ± 1.7 cm vs. 34.6 ± 1.3 cm [mean ± 1 S.D.]). Long-term follow-up of 195 (97.5%) of the children born to methyldopa-treated pregnant women (including those who began treatment between weeks 16 and 20) failed to uncover any significant adverse effect on the children. At four years of age, the <span class="product-label-link" type="condition" conceptid="436077" conceptname="Developmental delay">developmental delay</span> commonly seen in children born to hypertensive mothers was less evident in those whose mothers were treated with methyldopa during pregnancy than those whose mothers were untreated. The children of the treated group scored consistently higher than the children of the untreated group on five major indices of intellectual and motor development. At age 7 and one-half developmental scores and intelligence indices showed no significant differences in children of treated or untreated hypertensive women.</p>
</div>
</div>
<div class="Section" data-sectionCode="34080-2">
<a name="s8"></a><a name="section-6.7"></a><p></p>
<h2>Nursing Mothers</h2>
<p class="First">Methyldopa appears in breast milk. Therefore, caution should be exercised when methyldopa is given to a nursing woman.</p>
</div>
<div class="Section" data-sectionCode="34081-0">
<a name="s9"></a><a name="section-6.8"></a><p></p>
<h2>Pediatric Use</h2>
<p class="First">There are no well-controlled clinical trials in pediatric patients. Information on dosing in pediatric patients is supported by evidence from published literature regarding the treatment of <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">hypertension</span> in pediatric patients.  (See 
         
 
  <span class="Bold"><a href="#s13">DOSAGE AND ADMINISTRATION</a></span>.)
        

 </p>
</div>
<div class="Section" data-sectionCode="34082-8">
<a name="s10"></a><a name="section-6.9"></a><p></p>
<h2>Geriatric Use</h2>
<p class="First">Of the total number of subjects (1685) in clinical studies of methyldopa, 223 patients were 65 years of age and over while 33 patients were 75 years of age and over. No overall differences in safety or effectiveness were observed between these subjects and younger subjects, and other reported clinical experience has not identified differences in responses between the elderly and younger patients, but greater sensitivity of some older individuals cannot be ruled out. (See 
         
 
  <span class="Bold"><a href="#s13">DOSAGE AND ADMINISTRATION</a></span>.)
        

 </p>
<p>This drug is known to be substantially excreted by the kidney, and the risk of toxic reactions to this drug may be greater in patients with <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">impaired renal function</span>. Because elderly patients are more likely to have decreased renal function, care should be taken in dose selection and it may be useful to monitor renal function.</p>
</div>
</div>
<div class="Section" data-sectionCode="34084-4">
<a name="s11"></a><a name="section-7"></a><p></p>
<h1>ADVERSE REACTIONS</h1>
<p class="First">Sedation, usually transient, may occur during the initial period of therapy or whenever the dose is increased. <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">Headache</span>, <span class="product-label-link" type="condition" conceptid="437113" conceptname="Asthenia">asthenia</span>, or <span class="product-label-link" type="condition" conceptid="437113" conceptname="Asthenia">weakness</span> may be noted as early and transient symptoms. However, significant adverse effects due to methyldopa have been infrequent and this agent usually is well tolerated.</p>
<p>The following adverse reactions have been reported and, within each category, are listed in order of decreasing severity.</p>
<p><span class="Bold">Cardiovascular</span>: Aggravation of <span class="product-label-link" type="condition" conceptid="321318" conceptname="Angina pectoris">angina pectoris</span>, <span class="product-label-link" type="condition" conceptid="319835" conceptname="Congestive heart failure">congestive heart failure</span>, prolonged carotid sinus <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity</span>, <span class="product-label-link" type="condition" conceptid="319041" conceptname="Orthostatic hypotension">orthostatic hypotension</span> (decrease daily dosage), <span class="product-label-link" type="condition" conceptid="433595" conceptname="Edema">edema</span> or <span class="product-label-link" type="condition" conceptid="4134784" conceptname="Weight increased">weight gain</span>, <span class="product-label-link" type="condition" conceptid="4169095" conceptname="Bradycardia">bradycardia</span>.
      

 </p>
<p><span class="Bold">Digestive: </span><span class="product-label-link" type="condition" conceptid="4192640" conceptname="Pancreatitis">Pancreatitis</span>, <span class="product-label-link" type="condition" conceptid="4272488" conceptname="Colitis">colitis</span>, <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>, <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span>, <span class="product-label-link" type="condition" conceptid="29056" conceptname="Sialoadenitis">sialadenitis</span>, sore or "black" tongue, <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>, <span class="product-label-link" type="condition" conceptid="75860" conceptname="Constipation">constipation</span>, distension, <span class="product-label-link" type="condition" conceptid="4091513" conceptname="Passing flatus">flatus</span>, dryness of mouth.
      

 </p>
<p><span class="Bold">Endocrine: </span><span class="product-label-link" type="condition" conceptid="4030186" conceptname="Hyperprolactinemia">Hyperprolactinemia</span>.
      

 </p>
<p><span class="Bold">Hematologic: </span><span class="product-label-link" type="condition" conceptid="4145241" conceptname="Bone marrow depression">Bone marrow depression</span>, <span class="product-label-link" type="condition" conceptid="435224" conceptname="Leukopenia">leukopenia</span>, <span class="product-label-link" type="condition" conceptid="4218497" conceptname="Granulocytopenic disorder">granulocytopenia</span>, <span class="product-label-link" type="condition" conceptid="432870" conceptname="Thrombocytopenic disorder">thrombocytopenia</span>, <span class="product-label-link" type="condition" conceptid="435503" conceptname="Hemolytic anemia">hemolytic anemia</span>; positive tests for <span class="product-label-link" type="condition" conceptid="4163958" conceptname="Antinuclear antibody">antinuclear antibody</span>, LE cells, and rheumatoid factor, positive Coombs test.
      

 </p>
<p><span class="Bold">Hepatic: </span><span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">Liver disorders</span> including <span class="product-label-link" type="condition" conceptid="194990" conceptname="Inflammatory disease of liver">hepatitis</span>, <span class="product-label-link" type="condition" conceptid="137977" conceptname="Jaundice">jaundice</span>, <span class="product-label-link" type="condition" conceptid="438878" conceptname="Liver function tests abnormal">abnormal liver function tests</span> (see 
       
 
  <span class="Bold"><a href="#s5">WARNINGS</a></span>).
      

 </p>
<p><span class="Bold"><span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">Hypersensitivity</span>: </span><span class="product-label-link" type="condition" conceptid="314383" conceptname="Myocarditis">Myocarditis</span>, <span class="product-label-link" type="condition" conceptid="4138837" conceptname="Pericarditis">pericarditis</span>, <span class="product-label-link" type="condition" conceptid="4137275" conceptname="Vasculitis">vasculitis</span>, lupus-like syndrome, drug-related <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">fever</span>, <span class="product-label-link" type="condition" conceptid="4302954" conceptname="Disorder characterized by eosinophilia">eosinophilia</span>.
      

 </p>
<p><span class="Bold">Nervous System/Psychiatric: </span><span class="product-label-link" type="condition" conceptid="4140090" conceptname="Parkinsonism">Parkinsonism</span>, Bell’s <span class="product-label-link" type="condition" conceptid="440377" conceptname="Paralysis">palsy</span>, decreased mental acuity, involuntary choreoathetotic movements, symptoms of cerebrovascular insufficiency, <span class="product-label-link" type="condition" conceptid="432586" conceptname="Mental disorder">psychic disturbances</span> including <span class="product-label-link" type="condition" conceptid="4009184" conceptname="Dream anxiety disorder">nightmares</span> and reversible mild psychoses or <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span>, <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span>, sedation, <span class="product-label-link" type="condition" conceptid="437113" conceptname="Asthenia">asthenia</span> or <span class="product-label-link" type="condition" conceptid="437113" conceptname="Asthenia">weakness</span>, <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span>, light-headedness, <span class="product-label-link" type="condition" conceptid="4193492" conceptname="Acroparesthesia">paresthesias</span>.
      

 </p>
<p><span class="Bold">Metabolic: </span>Rise in BUN.
      

 </p>
<p><span class="Bold">Musculoskeletal: </span><span class="product-label-link" type="condition" conceptid="77074" conceptname="Joint pain">Arthralgia</span>, with or without <span class="product-label-link" type="condition" conceptid="4154927" conceptname="Joint swelling">joint swelling</span>; <span class="product-label-link" type="condition" conceptid="442752" conceptname="Muscle pain">myalgia</span>.
      

 </p>
<p><span class="Bold">Respiratory: </span><span class="product-label-link" type="condition" conceptid="4195085" conceptname="Nasal congestion">Nasal stuffiness</span>.
      

 </p>
<p><span class="Bold">Skin: </span><span class="product-label-link" type="condition" conceptid="443754" conceptname="Lyell's toxic epidermal necrolysis, subepidermal type">Toxic epidermal necrolysis</span>, <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span>.
      

 </p>
<p><span class="Bold">Urogenital: </span><span class="product-label-link" type="condition" conceptid="443800" conceptname="Amenorrhea">Amenorrhea</span>, <span class="product-label-link" type="condition" conceptid="78474" conceptname="Hypertrophy of breast">breast enlargement</span>, <span class="product-label-link" type="condition" conceptid="4168447" conceptname="Gynecomastia">gynecomastia</span>, lactation, <span class="product-label-link" type="condition" conceptid="4216771" conceptname="Impotence">impotence</span>, decreased libido.
      

 </p>
</div>
<div class="Section" data-sectionCode="34088-5">
<a name="s12"></a><a name="section-8"></a><p></p>
<h1>OVERDOSAGE</h1>
<p class="First">Acute overdosage may produce <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">acute hypotension</span> with other responses attributable to brain and gastrointestinal malfunction (excessive sedation, <span class="product-label-link" type="condition" conceptid="437113" conceptname="Asthenia">weakness</span>, <span class="product-label-link" type="condition" conceptid="4169095" conceptname="Bradycardia">bradycardia</span>, <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span>, light-headedness, <span class="product-label-link" type="condition" conceptid="75860" conceptname="Constipation">constipation</span>, <span class="product-label-link" type="condition" conceptid="4218984" conceptname="Abdominal distension">distention</span>, <span class="product-label-link" type="condition" conceptid="4091513" conceptname="Passing flatus">flatus</span>, <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span>, <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>, <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>).</p>
<p>In the event of overdosage, symptomatic and supportive measures should be employed. When ingestion is recent, gastric lavage or <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">emesis</span> may reduce absorption. When ingestion has been earlier, infusions may be helpful to promote urinary excretion. Otherwise, management includes special attention to cardiac rate and output, blood volume, electrolyte balance, <span class="product-label-link" type="condition" conceptid="192357" conceptname="Paralytic ileus">paralytic ileus</span>, urinary function and cerebral activity.</p>
<p>Sympathomimetic drugs [e.g., levarterenol, epinephrine, ARAMINE
       
 
  <span class="Sup">®1</span> (Metaraminol Bitartrate)] may be indicated. Methyldopa is dialyzable.
						
      

 </p>
<p>The oral LD
       
 
  <span class="Sub">50</span> of methyldopa is greater than 1.5 g/kg in both the mouse and the rat.
      

 </p>
<p>─ 
       
 
  <span class="Sup">1</span>ARAMINE
       
 
  <span class="Sup">®</span> is a registered trademark of Merck.
      

 </p>
</div>
<div class="Section" data-sectionCode="34068-7">
<a name="s13"></a><a name="section-9"></a><p></p>
<h1>DOSAGE AND ADMINISTRATION</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="s13.1"></a><a name="section-9.1"></a><p></p>
<h2>Adults</h2>
<div class="Section" data-sectionCode="42229-5">
<a name="s13.2"></a><a name="section-9.1.1"></a><p></p>
<h3>Initiation of Therapy</h3>
<p class="First">The usual starting dosage of methyldopa tablet is 250 mg two to three times a day in the first 48 hours. The daily dosage then may be increased or decreased, preferably at intervals of not less than two days, until an adequate response is achieved. To minimize the sedation, start dosage increases in the evening. By adjustment of dosage, morning <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span> may be prevented without sacrificing control of afternoon blood pressure.</p>
<p>When methyldopa is given to patients on other antihypertensives, the dose of these agents may need to be adjusted to effect a smooth transition. When methyldopa is given with anti-hypertensives other than thiazides, the initial dosage of methyldopa should be limited to 500 mg daily in divided doses; when methyldopa is added to a thiazide, the dosage of thiazide need not be changed.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s13.3"></a><a name="section-9.1.2"></a><p></p>
<h3>Maintenance of Therapy</h3>
<p class="First">The usual daily dosage of methyldopa is 500 mg to 2 g in two to four doses. Although occasional patients have responded to higher doses, the maximum recommended daily dosage is 3 g. Once an effective dosage range is attained, a smooth blood pressure response occurs in most patients in 12 to 24 hours. Since methyldopa has a relatively short duration of action, withdrawal is followed by return of <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">hypertension</span> usually within 48 hours. This is not complicated by an overshoot of blood pressure.</p>
<p>Occasionally tolerance may occur, usually between the second and third month of therapy. Adding a diuretic or increasing the dosage of methyldopa frequently will restore effective control of blood pressure. A thiazide may be added at any time during methyldopa therapy and is recommended if therapy has not been started with a thiazide or if effective control of blood pressure cannot be maintained on 2 g of methyldopa daily.</p>
<p>Methyldopa is largely excreted by the kidney and patients with <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">impaired renal function</span> may respond to smaller doses. <span class="product-label-link" type="condition" conceptid="135360" conceptname="Syncope">Syncope</span> in older patients may be related to an increased sensitivity and advanced arteriosclerotic vascular disease. This may be avoided by lower doses.</p>
</div>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s13.4"></a><a name="section-9.2"></a><p></p>
<h2>Pediatric Patients</h2>
<p class="First">Initial dosage is based on 10 mg/kg of body weight daily in two to four doses. The daily dosage then is increased or decreased until an adequate response is achieved. The maximum dosage is 65 mg/kg or 3 g daily, whichever is less (see 
         
 
  <span class="Bold"><a href="#s9">PRECAUTIONS: Pediatric Use</a></span>.)
        

 </p>
</div>
</div>
<div class="Section" data-sectionCode="34069-5">
<a name="s14"></a><a name="section-10"></a><p></p>
<h1>HOW SUPPLIED</h1>
<p class="First">Methyldopa Tablets, USP are supplied as film-coated tablets containing 125 mg, 250 mg or 500 mg of Methyldopa, USP. 
       
 
  <br> 
						The 125 mg tablets are round, convex, peach colored, tablets debossed with ‘AHI’ on one side and ‘M21’ on the other. They are available as follows:
      

 </p>
<p>NDC 16729-029-01 bottles of 100 tablets</p>
<p>The 250 mg tablets are round, convex, peach colored, tablets debossed with ‘AHI’ on one side and ‘M22’ on the other. They are available as follows:</p>
<p>NDC 16729-030-01 bottles of 100 tablets 
       
 
  <br> NDC 16729-030-16 bottles of 500 tablets 
       
 
  <br> NDC 16729-030-17 bottles of 1000 tablets
      

 </p>
<p>The 500 mg tablets are round, convex, peach colored, tablets debossed with ‘AHI’ on one side and ‘M23’ on the other. They are available as follows:</p>
<p>NDC 16729-031-01 bottles of 100 tablets 
       
 
  <br> NDC 16729-031-16 bottles of 500 tablets
      

 </p>
<p><span class="Bold">Store at 20° to 25°C (68° to 77°F). [See USP for Controlled Room Temperature.] Protect from light.</span></p>
<p>Dispense in a tight, light-resistant container as defined in the USP using a child-resistant closure.</p>
<p><span class="Bold">Manufactured For:</span></p>
<p>Accord Healthcare, Inc., 
       
 
  <br> 1009 Slater Road, Suite 210-B, 
       
 
  <br> Durham, NC 27703, USA.
      

 </p>
<p><span class="Bold">Manufactured By:</span></p>
<p>Intas Pharmaceuticals Limited, 
       
 
  <br> Plot No. : 457, 458, Village – Matoda, 
       
 
  <br> Bavla Road, Ta.- Sanand, 
       
 
  <br> Dist.- Ahmedabad – 382 210. India.
						
      

 </p>
<p>10 10934 1 638457</p>
<p>Issued May 2012</p>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="s15"></a><a name="section-11"></a><p></p>
<h1>PRINCIPAL DISPLAY PANEL</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="section-11.1"></a><p></p>
<h2>Methyldopa Tablets 125mg Label Text</h2>
<p class="First"><span class="Bold"> NDC 16729-029-01</span></p>
<p><span class="Bold"> Methyldopa</span></p>
<p><span class="Bold"> Tablets USP</span></p>
<p><span class="Bold"> 125 mg</span></p>
<p><span class="Bold"> Rx only</span></p>
<p><span class="Bold"> 100 Tablets</span></p>
<p><span class="Bold"> accord</span></p>
<div class="Figure"><img alt="Methyldopa Tablets 125mg Label" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=00206aae-7db1-4ae9-8500-b03fd6788d74&amp;name=container-125mg.jpg"></div>
</div>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="section-12"></a><p></p>
<h1>Methyldopa Tablets 250mg Label Text</h1>
<p class="First"><span class="Bold"> NDC 16729-030-01</span></p>
<p><span class="Bold"> Methyldopa</span></p>
<p><span class="Bold"> Tablets USP</span></p>
<p><span class="Bold"> 250 mg</span></p>
<p><span class="Bold"> Rx only</span></p>
<p><span class="Bold"> 100 Tablets</span></p>
<p><span class="Bold"> accord</span></p>
<div class="Figure"><img alt="Methyldopa Tablets 250mg Label" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=00206aae-7db1-4ae9-8500-b03fd6788d74&amp;name=container-250mg.jpg"></div>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="section-13"></a><p></p>
<h1>PRINCIPAL DISPLAY PANEL</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="section-13.1"></a><p></p>
<h2>Methyldopa Tablets 500mg Label Text</h2>
<p class="First"><span class="Bold"> NDC 16729-031-01</span></p>
<p><span class="Bold"> Methyldopa</span></p>
<p><span class="Bold"> Tablets USP</span></p>
<p><span class="Bold"> 500 mg</span></p>
<p><span class="Bold"> Rx only</span></p>
<p><span class="Bold"> 100 Tablets</span></p>
<p><span class="Bold"> accord</span></p>
<div class="Figure"><img alt="Methyldopa Tablets 500mg Label" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=00206aae-7db1-4ae9-8500-b03fd6788d74&amp;name=container-500mg.jpg"></div>
</div>
</div>
</div>
<div class="DataElementsTables">
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>METHYLDOPA 		
					</strong><br><span class="contentTableReg">methyldopa tablet, film coated</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:16729-029</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">ORAL</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">    
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>METHYLDOPA</strong> (METHYLDOPA ANHYDROUS) </td>
<td class="formItem">METHYLDOPA ANHYDROUS</td>
<td class="formItem">125 mg</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>STARCH, CORN</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>SODIUM STARCH GLYCOLATE TYPE A POTATO</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>POVIDONE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>CELLULOSE, MICROCRYSTALLINE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>MAGNESIUM STEARATE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>HYPROMELLOSES</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>FD&amp;C YELLOW NO. 6</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>TITANIUM DIOXIDE</strong></td>
<td class="formItem"> </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Characteristics</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Color</td>
<td class="formItem">orange (peach) </td>
<td class="formLabel">Score</td>
<td class="formItem">no score</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Shape</td>
<td class="formItem">ROUND</td>
<td class="formLabel">Size</td>
<td class="formItem">8mm</td>
</tr>
<tr class="formTableRowAlt">
<td class="formLabel">Flavor</td>
<td class="formItem"></td>
<td class="formLabel">Imprint Code</td>
<td class="formItem">AHI;M21</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Contains</td>
<td class="formItem">    </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:16729-029-01</td>
<td class="formItem">100  in 1 BOTTLE; Combination Product Type = C112160</td>
<td class="formItem">06/27/2012</td>
<td class="formItem">06/27/2012</td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">ANDA</td>
<td class="formItem">ANDA070070</td>
<td class="formItem">06/27/2012</td>
<td class="formItem">06/27/2012</td>
</tr>
</table></td></tr>
</tbody></table>
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>METHYLDOPA 		
					</strong><br><span class="contentTableReg">methyldopa tablet, film coated</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:16729-030</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">ORAL</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">    
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>METHYLDOPA</strong> (METHYLDOPA ANHYDROUS) </td>
<td class="formItem">METHYLDOPA ANHYDROUS</td>
<td class="formItem">250 mg</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>STARCH, CORN</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>SODIUM STARCH GLYCOLATE TYPE A POTATO</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>POVIDONE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>CELLULOSE, MICROCRYSTALLINE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>MAGNESIUM STEARATE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>HYPROMELLOSES</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>FD&amp;C YELLOW NO. 6</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>TITANIUM DIOXIDE</strong></td>
<td class="formItem"> </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Characteristics</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Color</td>
<td class="formItem">orange (peach) </td>
<td class="formLabel">Score</td>
<td class="formItem">no score</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Shape</td>
<td class="formItem">ROUND</td>
<td class="formLabel">Size</td>
<td class="formItem">10mm</td>
</tr>
<tr class="formTableRowAlt">
<td class="formLabel">Flavor</td>
<td class="formItem"></td>
<td class="formLabel">Imprint Code</td>
<td class="formItem">AHI;M22</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Contains</td>
<td class="formItem">    </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:16729-030-01</td>
<td class="formItem">100  in 1 BOTTLE; Combination Product Type = C112160</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRow">
<th scope="row" class="formItem">2</th>
<td class="formItem">NDC:16729-030-16</td>
<td class="formItem">500  in 1 BOTTLE; Combination Product Type = C112160</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">3</th>
<td class="formItem">NDC:16729-030-17</td>
<td class="formItem">1000  in 1 BOTTLE; Combination Product Type = C112160</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">ANDA</td>
<td class="formItem">ANDA070084</td>
<td class="formItem">06/27/2012</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>METHYLDOPA 		
					</strong><br><span class="contentTableReg">methyldopa tablet, film coated</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:16729-031</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">ORAL</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">    
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>METHYLDOPA</strong> (METHYLDOPA ANHYDROUS) </td>
<td class="formItem">METHYLDOPA ANHYDROUS</td>
<td class="formItem">500 mg</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>SODIUM STARCH GLYCOLATE TYPE A POTATO</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>POVIDONE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>CELLULOSE, MICROCRYSTALLINE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>MAGNESIUM STEARATE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>HYPROMELLOSES</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>FD&amp;C YELLOW NO. 6</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>TITANIUM DIOXIDE</strong></td>
<td class="formItem"> </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Characteristics</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Color</td>
<td class="formItem">orange (peach) </td>
<td class="formLabel">Score</td>
<td class="formItem">no score</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Shape</td>
<td class="formItem">ROUND</td>
<td class="formLabel">Size</td>
<td class="formItem">13mm</td>
</tr>
<tr class="formTableRowAlt">
<td class="formLabel">Flavor</td>
<td class="formItem"></td>
<td class="formLabel">Imprint Code</td>
<td class="formItem">AHI;M23</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Contains</td>
<td class="formItem">    </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:16729-031-01</td>
<td class="formItem">100  in 1 BOTTLE; Combination Product Type = C112160</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRow">
<th scope="row" class="formItem">2</th>
<td class="formItem">NDC:16729-031-16</td>
<td class="formItem">500  in 1 BOTTLE; Combination Product Type = C112160</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">ANDA</td>
<td class="formItem">ANDA070085</td>
<td class="formItem">06/27/2012</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite"><tr><td colspan="4" class="formHeadingReg">
<span class="formHeadingTitle">Labeler - </span>Accord Healthcare Inc.
							(604222237)
						</td></tr></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite"><tr><td colspan="4" class="formHeadingReg">
<span class="formHeadingTitle">Registrant - </span>Accord Healthcare Inc. (604222237)</td></tr></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Establishment</span></td></tr>
<tr>
<th scope="col" class="formTitle">Name</th>
<th scope="col" class="formTitle">Address</th>
<th scope="col" class="formTitle">ID/FEI</th>
<th scope="col" class="formTitle">Business Operations</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">Intas Pharmaceuticals Limited</td>
<td class="formItem"></td>
<td class="formItem">725927649</td>
<td class="formItem">manufacture(16729-029, 16729-030, 16729-031)</td>
</tr>
</table>
</div>
<p><div class="EffectiveDate">Revised: 4/2015<div class="DocumentMetadata">
<div>
<a href="javascript:toggleMixin();">Document Id: </a>13c9ab06-98ef-728a-e054-00144ff88e88</div>
<div>Set id: 00206aae-7db1-4ae9-8500-b03fd6788d74</div>
<div>Version: 2</div>
<div>Effective Time: 20150415</div>
</div>
</div> <div class="DistributorName">Accord Healthcare Inc.</div></p>
</body></html>
